(2R,3R,4S,5R,6S)-2-(Hydroxymethyl)-6-[[(2R,3S,4S,5R)-3,5,6-trihydroxy-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol

Term ID

CHEBI:150883

Synonyms

alpha-D-galacto-hexopyranosyl-(1->3)-[alpha-D-galacto-hexopyranosyl-(1->6)]-D-galacto-hexopyranose
Gal(a1-3)[Gal(a1-6)]Gal

Definition

References

glygen:G44009SU
glytoucan:G44009SU

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2R,3R,4S,5R,6S)-2-(Hydroxymethyl)-6-[[(2R,3S,4S,5R)-3,5,6-trihydroxy-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol

Phenotype where environments contain (2R,3R,4S,5R,6S)-2-(Hydroxymethyl)-6-[[(2R,3S,4S,5R)-3,5,6-trihydroxy-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol

Phenotype modified by environments containing (2R,3R,4S,5R,6S)-2-(Hydroxymethyl)-6-[[(2R,3S,4S,5R)-3,5,6-trihydroxy-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol

Phenotype affecting (2R,3R,4S,5R,6S)-2-(Hydroxymethyl)-6-[[(2R,3S,4S,5R)-3,5,6-trihydroxy-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol

Human Disease Model